TY - JOUR
T1 - Factors That Affect Risk for Hepatocellular Carcinoma and Effects of Surveillance
AU - Yang, Ju Dong
AU - Harmsen, William S.
AU - Slettedahl, Seth W.
AU - Chaiteerakij, Roongruedee
AU - Enders, Felicity T.
AU - Therneau, Terry M.
AU - Orsini, Lucinda
AU - Kim, W. Ray
AU - Roberts, Lewis R.
N1 - Funding Information:
Funding This work was supported by Bristol-Myers Squibb.
PY - 2011/7
Y1 - 2011/7
N2 - Background & Aims: The incidence of hepatocellular carcinoma (HCC) in the United States is increasing. Surveillance may affect the stage at diagnosis and consequently the treatment options available for HCC. We evaluated risk factors for HCC, the proportion of cases detected via surveillance, tumor characteristics, treatment approaches, and overall patient survival in a referral center cohort. Methods: The study included all patients diagnosed with HCC at the Mayo Clinic, Rochester, Minnesota, from 2007 to 2009 (n = 460). Clinical information was retrospectively abstracted from the medical record. Results: Hepatitis C virus (HCV, 36%), alcohol use (29%), and nonalcoholic fatty liver disease (NAFLD, 13%) were the most common risk factors for HCC. HCV was present in 56% of patients younger than 60. NAFLD was present in 19% of patients older than 60. HCC was detected during surveillance in 31% of patients. Patients with worse liver function were more likely to be on surveillance. Transarterial chemoembolization, surgical resection, and liver transplantation were the most common treatment approaches for HCC. Patients diagnosed with HCC during surveillance had less advanced disease, were more likely to be eligible for potentially curative treatments, and had increased survival times (P < .001). Conclusions: At a major US referral center, the predominant HCC etiologies were HCV, alcohol use, and NAFLD. HCCs were detected during surveillance in the minority of patients. HCCs detected during surveillance were of less advanced stage, and patients were more likely to receive treatment that prolonged their survival.
AB - Background & Aims: The incidence of hepatocellular carcinoma (HCC) in the United States is increasing. Surveillance may affect the stage at diagnosis and consequently the treatment options available for HCC. We evaluated risk factors for HCC, the proportion of cases detected via surveillance, tumor characteristics, treatment approaches, and overall patient survival in a referral center cohort. Methods: The study included all patients diagnosed with HCC at the Mayo Clinic, Rochester, Minnesota, from 2007 to 2009 (n = 460). Clinical information was retrospectively abstracted from the medical record. Results: Hepatitis C virus (HCV, 36%), alcohol use (29%), and nonalcoholic fatty liver disease (NAFLD, 13%) were the most common risk factors for HCC. HCV was present in 56% of patients younger than 60. NAFLD was present in 19% of patients older than 60. HCC was detected during surveillance in 31% of patients. Patients with worse liver function were more likely to be on surveillance. Transarterial chemoembolization, surgical resection, and liver transplantation were the most common treatment approaches for HCC. Patients diagnosed with HCC during surveillance had less advanced disease, were more likely to be eligible for potentially curative treatments, and had increased survival times (P < .001). Conclusions: At a major US referral center, the predominant HCC etiologies were HCV, alcohol use, and NAFLD. HCCs were detected during surveillance in the minority of patients. HCCs detected during surveillance were of less advanced stage, and patients were more likely to receive treatment that prolonged their survival.
KW - Etiology
KW - Liver Cancer
KW - Screening
KW - Surveillance
KW - Survival
KW - Therapy
KW - Treatment
UR - http://www.scopus.com/inward/record.url?scp=79959361853&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=79959361853&partnerID=8YFLogxK
U2 - 10.1016/j.cgh.2011.03.027
DO - 10.1016/j.cgh.2011.03.027
M3 - Article
C2 - 21459158
AN - SCOPUS:79959361853
SN - 1542-3565
VL - 9
SP - 617-623.e1
JO - Clinical Gastroenterology and Hepatology
JF - Clinical Gastroenterology and Hepatology
IS - 7
ER -